Cyclin D binding factor and uses thereof (SJ-96-0010)
- *Abstract
-
The cyclin D-binding Myb-like protein DMP1 is a tumor suppressor. DMP1 binding to DNA activates transcription, which can be inhibited by direct binding of D-type cyclins. DMP1 inhibits cell cycle progression and a manuscript in the October 12, 2007 edition of Cancer Cell shows DMP1's involvement in lung cancer. This research indicates that loss of heterozygosity of the hDMP1 gene is detectable in approximately 35% of human lung carcinomas. DMP1 and its analogs may serve as potential prodrugs for cancer therapy and valid targets in anti-cancer drug screening assays. Detection of the loss of the gene or protein may serve as a diagnostic and/or prognostic test for lung cancer.
Key words: Tumor suppressor, cancer therapy prodrug, cancer drug screening target, lung cancer diagnostic
Granted patents or published applications: U.S. Pat. Nos. 6,303,772, 6,673,902 and 6,180,763
Related scientific references: Mallakin, A., et. al. "Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer" Cancer Cell 12, 381-394, Oct 2007.
Inoue K, et. al. "Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis" Genes Dev. 14: 1797-1809 (2000).
Hirai H and Sherr C.J. "Interaction of D-type cyclins with a novel myb-like transcription factor" Mol Cell Biol 16(11): 6457-6467 (1996).
- 國家/地區
- 美國
